Integra LifeSciences Holdings Corporation (IART) - What Are Researchers Saying About This Stock?

Key Points

• Analysts are broadly cautious on Integra LifeSciences: ten firms give the stock an average “Reduce” rating, and their average one-year price target is $16.12. Ratings comprise three sells, five holds, and two buys.
• In its latest reported quarter, Integra earned $0.59 per share, topping the $0.56 consensus estimate, but revenue of $411.18 million came in below analysts’ $413.16 million forecast.
• The shares fell 5% in Friday’s mid-day trading to $13.42. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) has earned an average rating of "Reduce" from the ten ratings firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $16.12.

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $17.00 to $14.00 and set an "underweight" rating on the stock in a research report on Thursday, October 22nd. UBS Group set a $14.00 price target on Integra LifeSciences and gave the stock a "neutral" rating in a research report on Tuesday, October 27th. Weiss Ratings raised shares of Integra LifeSciences from a "sell (e+)" rating to a "sell (d+)" rating in a research report on Monday, October 26th. Wall Street Zen upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Saturday, October 31st. Finally, Citigroup restated an "outperform" rating on shares of Integra LifeSciences in a research note on Thursday, October 22nd.

Institutional Trading of Integra LifeSciences

A number of hedge funds have recently bought and sold shares of IART. Inspire Investing LLC boosted its position in Integra LifeSciences by 5.2% in the third quarter. Inspire Investing LLC now owns 39,168 shares of the life sciences company's stock worth $638,000 after purchasing an additional 1,929 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Integra LifeSciences by 1.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 152,837 shares of the life sciences company's stock worth $2,488,000 after purchasing an additional 2,889 shares during the period. Sequoia Financial Advisors LLC lifted its stake in shares of Integra LifeSciences by 27.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company's stock worth $134,000 after purchasing an additional 3,059 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of Integra LifeSciences in the second quarter worth approximately $82,000. Finally, Integrated Wealth Concepts LLC bought a new stake in Integra LifeSciences during the second quarter valued at approximately $84,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Trading Down 5.0%

Integra LifeSciences stock traded down $0.70 during mid-day trading on Friday, hitting $13.42. The company's stock had a trading volume of 871,884 shares, compared to its average volume of 1,248,525. The business has a 50 day moving average price of $14.55 and a 200-day moving average price of $14.12. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $20.49. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of 78.94, a price-to-earnings-growth ratio of 0.53 and a beta of 1.28.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.03. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. The firm had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same quarter in the prior year, the firm posted ($0.07) earnings per share. As a group, analysts forecast that Integra LifeSciences will post 2.34 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra's neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.